Yi Hu

38PUBLICATIONS
115CO-AUTHORS
Molecular targetsHaematological tumoursPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (38)

|Oct 13, 2026
First-line treatment outcomes in HER2-altered advanced NSCLC: a real-world multi-center study comparing trastuzumab deruxtecan with conventional therapies and analysis by HER2/EGFR co-alteration status.

|Sep 03, 2026
Recruited Monocyte-Derived Macrophages Drive T Cell Inflammation in Immune Checkpoint Inhibitor-Mediated Pneumonitis.

|Jun 17, 2026
Circadian-immune-related gene signature for lung squamous cell carcinoma: machine learning and multi-omics analysis.

|Apr 13, 2026
Real-world efficacy and safety of disitamab vedotin (RC48) plus PD-1 inhibitors in advanced urothelial carcinoma: a single-center retrospective study.

Ya-Hui Lv, Xiao-Ran Cui, Lu Yu

|Mar 02, 2026
Efficacy and safety of immunotherapy in elderly patients with advanced non-small cell lung cancer: a real-world study stratified by age.

Yi Dong, Mei-Cen Liu, Yun-Ye Mao

|Feb 12, 2026
Grade 3 and above opportunistic pneumonia or drug-induced interstitial lung disease during tyrosine-kinase inhibitor treatment for advanced non-small-cell lung cancer with RET fusion mutations: coexistence of risks and opportunities.

An Wang, Tao Li, Yun-Ye Mao

Pageof 7

Frequent Collaborators

13 joint publications

Tao Li

6 joint publications

Xiaoran Cui

5 joint publications

An Wang

4 joint publications

Yunye Mao